Novo Nordisk (NVO) shares fell nearly 7% premarket on Monday, the most since December, after the drugmaker said its ...

Seven & i Holdings said in a letter to shareholders Monday that Couche-Tard recently agreed to jointly explore a potential sale of some stores prior to signing a takeover agreement.

CagriSema produced an average 15.7% weight reduction in overweight or obese individuals with type 2 diabetes, according to ...

Novo Nordisk NVO has achieved the primary endpoint in the second late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema, in patients with obesity and type 2 ...

Novo Nordisk (NVO) shares fell nearly 7% premarket on Monday, the most since December, after the drugmaker said its investigational next-generation obesity drug CagriSema caused 15.7% weight loss ...

The trial of CagriSema in patients who were obese or overweight and with type 2 diabetes failed to show a clear superiority to a drug from rival Eli Lilly, analysts said. The CagriSema group had ...

Incidentally, shares of Novo Nordisk sank 17% prior to the FDA drug shortage supply announcement on disappointing results of its experimental obesity drug CagriSema, which only showed a 22.7% ...

For the final quarter of 2024, the fund returned -5.12%, outpacing the -7.58% result of the benchmark MSCI All Country World ...

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release ...

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release ...